JP2016153424A5 - - Google Patents

Download PDF

Info

Publication number
JP2016153424A5
JP2016153424A5 JP2016097613A JP2016097613A JP2016153424A5 JP 2016153424 A5 JP2016153424 A5 JP 2016153424A5 JP 2016097613 A JP2016097613 A JP 2016097613A JP 2016097613 A JP2016097613 A JP 2016097613A JP 2016153424 A5 JP2016153424 A5 JP 2016153424A5
Authority
JP
Japan
Prior art keywords
dioxol
difluoro
benzo
formula
cyclopropanecarboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016097613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016153424A (ja
JP6158985B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016153424A publication Critical patent/JP2016153424A/ja
Publication of JP2016153424A5 publication Critical patent/JP2016153424A5/ja
Application granted granted Critical
Publication of JP6158985B2 publication Critical patent/JP6158985B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2016097613A 2004-01-30 2016-05-16 Ａｔｐ結合カセットトランスポーターのモジュレーター Expired - Lifetime JP6158985B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54056404P 2004-01-30 2004-01-30
US60/540,564 2004-01-30
US60350304P 2004-08-20 2004-08-20
US60/603,503 2004-08-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015019897A Division JP2015091875A (ja) 2004-01-30 2015-02-04 Ａｔｐ結合カセットトランスポーターのモジュレーター

Publications (3)

Publication Number Publication Date
JP2016153424A JP2016153424A (ja) 2016-08-25
JP2016153424A5 true JP2016153424A5 (enExample) 2017-03-30
JP6158985B2 JP6158985B2 (ja) 2017-07-05

Family

ID=34841105

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006551487A Expired - Lifetime JP4960708B2 (ja) 2004-01-30 2005-01-31 Ａｔｐ結合カセットトランスポーターのモジュレーター
JP2012009781A Expired - Lifetime JP5669319B2 (ja) 2004-01-30 2012-01-20 Ａｔｐ結合カセットトランスポーターのモジュレーター
JP2014021918A Expired - Lifetime JP5840239B2 (ja) 2004-01-30 2014-02-07 Ａｔｐ結合カセットトランスポーターのモジュレーター
JP2015019897A Pending JP2015091875A (ja) 2004-01-30 2015-02-04 Ａｔｐ結合カセットトランスポーターのモジュレーター
JP2016097613A Expired - Lifetime JP6158985B2 (ja) 2004-01-30 2016-05-16 Ａｔｐ結合カセットトランスポーターのモジュレーター

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2006551487A Expired - Lifetime JP4960708B2 (ja) 2004-01-30 2005-01-31 Ａｔｐ結合カセットトランスポーターのモジュレーター
JP2012009781A Expired - Lifetime JP5669319B2 (ja) 2004-01-30 2012-01-20 Ａｔｐ結合カセットトランスポーターのモジュレーター
JP2014021918A Expired - Lifetime JP5840239B2 (ja) 2004-01-30 2014-02-07 Ａｔｐ結合カセットトランスポーターのモジュレーター
JP2015019897A Pending JP2015091875A (ja) 2004-01-30 2015-02-04 Ａｔｐ結合カセットトランスポーターのモジュレーター

Country Status (10)

Country Link
US (1) US8759335B2 (enExample)
EP (2) EP3219709B1 (enExample)
JP (5) JP4960708B2 (enExample)
CN (1) CN1938279B (enExample)
AU (1) AU2005210474B2 (enExample)
BR (1) BRPI0507278A (enExample)
CA (1) CA2554796A1 (enExample)
ES (2) ES2791303T3 (enExample)
MX (1) MXPA06008606A (enExample)
WO (1) WO2005075435A1 (enExample)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06002567A (es) 2003-09-06 2006-09-04 Vertex Pharma Moduladores de transportadores con casete de union de atp.
EP1682127B1 (en) * 2003-11-14 2009-07-29 Vertex Pharmaceuticals Incorporated Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
MX341797B (es) 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
EP1820504A1 (en) * 2004-11-15 2007-08-22 Taisho Pharmaceutical Co., Ltd Imine compound
MX2008002019A (es) 2005-08-11 2008-04-16 Vertex Pharma Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
CN101312722A (zh) 2005-10-06 2008-11-26 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
ES2778846T3 (es) 2005-11-08 2020-08-12 Vertex Pharma Moduladores heterocíclicos de transportadores de casete de unión a ATP
AU2012201325B2 (en) * 2005-11-08 2012-05-03 Vertex Pharmaceuticals Incorporated Heterocyclic Modulators of ATP-Binding Cassette Transporters
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
AU2006336504C9 (en) 2005-12-28 2015-05-14 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP1976839A4 (en) * 2006-01-26 2011-06-15 Foldrx Pharmaceuticals Inc COMPOUNDS AND METHOD FOR MODULATING A PROTEIN TRANSPORT
NZ596889A (en) 2006-04-07 2013-06-28 Vertex Pharma Use of amide indole derivatives as modulators of ATP-binding cassette transporters
AU2013205183B2 (en) * 2006-04-07 2016-07-28 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
HUE034579T2 (en) 2006-11-03 2018-02-28 Vertex Pharma Azaindole derivatives as CFTR modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US8318935B2 (en) 2007-05-07 2012-11-27 Novartis Ag Organic compounds 75074
CA2687715A1 (en) * 2007-05-09 2008-11-20 Traffick Therapeutics Inc. Screening assay to identify correctors of protein trafficking defects
CN102863432B (zh) * 2007-05-09 2016-09-07 沃泰克斯药物股份有限公司 Cftr调节剂
JP2010528035A (ja) * 2007-05-25 2010-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネル調節物質およびその使用
WO2009003289A1 (en) * 2007-07-03 2009-01-08 The University Of British Columbia Small molecule correctors of deltaf508 cftr trafficking
SG187396A1 (en) 2007-07-19 2013-02-28 Lundbeck & Co As H 5-membered heterocyclic amides and related compounds
HUE028426T2 (en) 2007-08-24 2016-12-28 Vertex Pharma Isothiazolopyridinones for (inter alia) treating cystic fibrosis
AU2013231151B2 (en) * 2007-11-16 2015-06-25 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of ATP-Binding Cassette transporters
ES2556080T3 (es) * 2007-11-16 2016-01-12 Vertex Pharmaceuticals Incorporated Moduladores de isoquinolina de transportadores de casete de unión a ATP
WO2009076142A2 (en) 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
KR20150063170A (ko) 2007-12-07 2015-06-08 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
US20100036130A1 (en) * 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EA201070699A1 (ru) * 2007-12-07 2011-02-28 Вертекс Фармасьютикалз Инкорпорейтед Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
EP2231280B1 (en) 2007-12-10 2016-08-10 Novartis AG Amiloride-like Pyrazine-carboxamides as ENaC blockers
AU2015228930B2 (en) * 2008-02-28 2017-02-23 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR modulators
AU2013205162B2 (en) * 2008-02-28 2015-07-09 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR modulators
CN106432213A (zh) * 2008-02-28 2017-02-22 沃泰克斯药物股份有限公司 作为cftr调节剂的杂芳基衍生物
AU2013270464B2 (en) * 2008-03-31 2016-05-26 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
EP2615085B1 (en) * 2008-03-31 2015-08-26 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
BRPI0915018A2 (pt) 2008-06-10 2015-10-27 Novartis Ag compostos orgânicos
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
AU2009296271A1 (en) * 2008-09-29 2010-04-01 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
NZ592685A (en) 2008-10-23 2013-04-26 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
PL2404908T3 (pl) 2009-02-27 2014-12-31 Teijin Ltd Sposób wytwarzania podstawionej fenylem pochodnej heterocyklicznej przez sprzężenie z użyciem katalizatora metalu przejściowego
MX384179B (es) 2009-03-20 2025-03-14 Vertex Pharma Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quística.
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
WO2011093352A1 (ja) * 2010-01-27 2011-08-04 武田薬品工業株式会社 チアゾール誘導体
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
BR112012026255A2 (pt) 2010-04-07 2017-03-14 Vertex Pharma composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
CN102933206A (zh) 2010-04-07 2013-02-13 弗特克斯药品有限公司 3-(6-(1-(2，2-二氟苯并[d][1，3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式
NZ603044A (en) 2010-04-22 2015-08-28 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
RU2745977C2 (ru) 2010-04-22 2021-04-05 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
WO2011133953A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
AU2011242452A1 (en) 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
SG187843A1 (en) 2010-08-27 2013-03-28 Teijin Pharma Ltd Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using a palladium compound
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2651930B1 (en) * 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
KR101985044B1 (ko) 2011-11-08 2019-05-31 버텍스 파마슈티칼스 인코포레이티드 Atp-결합 카세트 수송체의 조절제
TWI640519B (zh) * 2011-11-29 2018-11-11 泰緯生命科技股份有限公司 Ｈｅｃ１活性調控因子及其調節方法
DK2806859T3 (da) 2012-01-25 2019-08-05 Vertex Pharma Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2013158121A1 (en) 2012-04-20 2013-10-24 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2858645A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
ITMI20122065A1 (it) 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
MX368263B (es) * 2013-05-07 2019-09-26 Galapagos Nv Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
JP6522602B2 (ja) 2013-07-02 2019-05-29 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
TW201506024A (zh) 2013-07-02 2015-02-16 必治妥美雅史谷比公司 作為有效ｒｏｃｋ抑制劑的三環甲醯胺衍生物
DK3068392T5 (da) 2013-11-12 2021-09-20 Vertex Pharma Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
SG10201913575VA (en) 2014-04-15 2020-02-27 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP3798214B1 (en) 2014-10-06 2022-09-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
EP3212189B1 (en) 2014-10-31 2020-09-09 AbbVie Overseas S.à r.l. Substituted chromanes and method of use
WO2016081556A1 (en) 2014-11-18 2016-05-26 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
CN104693164B (zh) * 2015-03-31 2017-03-08 衢州康鹏化学有限公司 一种 2，2‑二氟胡椒酸甲酯的制备方法
US9840513B2 (en) * 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
PT3394083T (pt) * 2015-12-24 2021-12-07 Univ California Derivados de n-[5-[(3,4-dimetoxifenil)metil]-1,3,4-tiadiazol-2-il]-2-metoxi-benzenoacetamida e compostos relacionados como ativadores de cftr para tratar a obstipação ou colestase
PT3394040T (pt) 2015-12-24 2022-03-24 Univ California Reguladores de cftr e seus métodos de uso
AR108175A1 (es) * 2016-04-06 2018-07-25 Innovative Molecules Gmbh Compuestos antivíricos de tiazol acetamida
SG10201913595YA (en) 2016-09-30 2020-02-27 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2018107040A1 (en) * 2016-12-09 2018-06-14 Vertex Pharmaceuticals Incorporated 1-(2-fluorophenyl)-n-[1-(2-fluoro-4-pyridyl)pyrazol-3-yl]cyclopropanecarboxamide, its solid forms and pharmaceutical uses thereof
US20180251431A1 (en) * 2016-12-09 2018-09-06 Vertex Pharmaceuticals Incorporated 1,3-substituted pyrazole compounds useful for reduction of very long chain fatty acid levels
MA49235B1 (fr) 2016-12-09 2021-02-26 Vertex Pharma Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
IT201700028184A1 (it) 2017-03-14 2018-09-14 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento della fibrosi cistica
IT201700028127A1 (it) * 2017-03-14 2018-09-14 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento della fibrosi cistica
US10968225B2 (en) 2017-03-14 2021-04-06 Fondazione Istituto Italiano Di Tecnologia Compounds and compositions for the treatment of cystic fibrosis
EP3634402B1 (en) 2017-06-08 2026-01-21 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
CN111629730A (zh) 2017-08-24 2020-09-04 加利福尼亚大学董事会 眼部药物组合物
EP4209491A1 (en) 2017-10-05 2023-07-12 Innovative Molecules GmbH Enantiomers of substituted thiazoles as antiviral compounds
IL273831B2 (en) 2017-10-19 2024-10-01 Vertex Pharma Crystalline forms and compositions of cftr modulators
CN111757874B (zh) 2017-12-08 2024-03-08 弗特克斯药品有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3752510B1 (en) 2018-02-15 2022-12-07 Vertex Pharmaceuticals Incorporated Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
JP7560011B2 (ja) 2018-09-09 2024-10-02 カナートファーマ アーゲー 脳血管状態を治療するためのｃｆｔｒモジュレーターの使用
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
CN110117263B (zh) * 2019-06-11 2020-12-25 湖南中医药大学 2-氨基-5-酰基噻唑衍生物及其合成方法
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
KR20220064366A (ko) 2019-08-14 2022-05-18 버텍스 파마슈티칼스 인코포레이티드 Cftr 조절제의 결정질 형태
WO2021113806A1 (en) * 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113809A1 (en) * 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
CN115916776A (zh) * 2020-06-09 2023-04-04 艾尼莫生物科技公司 胶原蛋白1翻译抑制剂及其使用方法
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CA3188787A1 (en) 2020-08-13 2022-02-17 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
JP7688331B2 (ja) * 2020-09-07 2025-06-04 日産化学株式会社 １，３，４－オキサジアゾール－２－アミン化合物の製造方法
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA3204725A1 (en) 2020-12-10 2022-06-16 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN113527225B (zh) * 2021-07-15 2022-11-18 南昌大学 一种丙烯酰噻二唑衍生物及其制备方法和应用
WO2023111996A1 (en) 2021-12-17 2023-06-22 Reglagene Holding, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
KR20250176573A (ko) 2023-02-28 2025-12-19 레글라진, 아이엔씨. 건강 상태의 치료를 위한 소분자 제조 및 사용을 위한 조성물 및 방법
US20250122171A1 (en) * 2023-09-20 2025-04-17 Deep Apple Therapeutics, Inc. Substituted Amine Compounds, Compositions and Methods of Use
KR20250121245A (ko) * 2024-02-02 2025-08-12 삼진제약주식회사 MRGPRX2 (Mas-related G-protein coupled receptor member X2) 길항제로서 신규 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
IL135176A0 (en) 1997-11-10 2001-05-20 Bristol Myers Squibb Co Benzothiazole derivatives and pharmaceutical compositions containing the same
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
PT1169038E (pt) * 1999-04-15 2012-10-26 Bristol Myers Squibb Co Inibidores cíclicos da proteína tirosina cinase
GEP20053476B (en) 1999-08-12 2005-03-25 Upjohn Co 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
RU2259370C2 (ru) * 1999-11-18 2005-08-27 Новартис Аг Аминогетероцикламидные производные, обладающие пестицидной активностью
WO2001046165A2 (en) * 1999-12-16 2001-06-28 Novartis Ag N-heteroaryl-amides and their use as parasiticides
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
JP4742333B2 (ja) 2000-11-13 2011-08-10 日本農薬株式会社 Ｎ−チアジアゾリルシクロプロパンカルボン酸アミド類およびこれを有効成分とする殺虫、殺ダニ剤
WO2002088090A2 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
JP2005524668A (ja) * 2002-03-01 2005-08-18 スミスクライン ビーチャム コーポレーション ジアミノピリミジン類及びそれらの血管新生阻害薬としての使用
WO2003084544A2 (en) * 2002-04-04 2003-10-16 Cv Therapeutics, Inc. Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
JP2006514684A (ja) 2002-10-30 2006-05-11 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｒｏｃｋおよび他のプロテインキナーゼとして有用な組成物
AU2003286757B2 (en) * 2002-11-01 2009-06-04 Merck Sharp & Dohme Corp. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
WO2004056744A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
JP4716734B2 (ja) * 2003-01-06 2011-07-06 イーライ リリー アンド カンパニー グルコキナーゼ活性化物質としての置換されたアリールシクロプロピルアセトアミド
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP1670787B1 (en) * 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
US20070129383A1 (en) * 2003-10-17 2007-06-07 Hiroshi Kuramochi Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof
EP1689721B1 (en) * 2003-11-26 2010-07-14 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
US7977322B2 (en) * 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
MX2008002019A (es) * 2005-08-11 2008-04-16 Vertex Pharma Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
ES2778846T3 (es) * 2005-11-08 2020-08-12 Vertex Pharma Moduladores heterocíclicos de transportadores de casete de unión a ATP
AU2006336504C9 (en) * 2005-12-28 2015-05-14 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7645789B2 (en) * 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
NZ596889A (en) * 2006-04-07 2013-06-28 Vertex Pharma Use of amide indole derivatives as modulators of ATP-binding cassette transporters
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
ES2556080T3 (es) * 2007-11-16 2016-01-12 Vertex Pharmaceuticals Incorporated Moduladores de isoquinolina de transportadores de casete de unión a ATP
CN106432213A (zh) * 2008-02-28 2017-02-22 沃泰克斯药物股份有限公司 作为cftr调节剂的杂芳基衍生物
EP2615085B1 (en) * 2008-03-31 2015-08-26 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators

Similar Documents

Publication Publication Date Title
JP2016153424A5 (enExample)
JP2018024670A5 (enExample)
JP2014138100A5 (enExample)
JP2019194236A5 (enExample)
JP2021502388A5 (enExample)
JP2017222697A5 (enExample)
JP2017035491A5 (ja) 頭蓋内出血の治療のための方法および装置
JP2018531290A5 (enExample)
JP2009149903A5 (enExample)
JP2010501534A5 (enExample)
JP2013173781A5 (enExample)
JP2020515557A5 (enExample)
JP2015522045A5 (enExample)
JP2013005803A5 (enExample)
JP2017214410A5 (enExample)
JP2014028813A5 (enExample)
JP2018116258A5 (enExample)
JP2019089762A5 (enExample)
JP2015199738A5 (enExample)
JP2013532130A5 (enExample)
JP2018150298A5 (enExample)
JP2014235432A5 (enExample)
JP2016000169A5 (enExample)
JP2018030858A5 (enExample)
JP2012094862A5 (enExample)